Simplify Logo

Full-Time

Sr. Manager

Supply Chain Planning

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Hardware
Biotechnology

Compensation Overview

$165k - $185kAnnually

Senior, Expert

San Carlos, CA, USA

Category
Supply Chain Management
Operations & Logistics
Required Skills
Communications
PowerPoint/Keynote/Slides
Requirements
  • Working experience with global clinical trials and IRT systems is a must
  • Working knowledge of cGMPs and familiarity with US and EU regulations
  • Working knowledge of drug development process (Phase I-IV)
  • Excellent interpersonal, verbal, and written communication skills are essential in this collaborative, fast-paced, dynamic environment
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within established timelines
  • Strong attention to detail with excellent follow-up
  • Proficient in Microsoft Outlook, Word, Excel, PowerPoint
  • BS/BA degree in Life Science or a closely related field.
  • 6-8 years of experience in a pharmaceutical or biotechnology company
  • ASCM CPIM/CSCP certifications preferred
Responsibilities
  • Develop supply plans for all Corcept clinical studies
  • Perform scenario planning to support decision-making
  • Provide clinical supply and risk mitigation recommendations
  • Oversee inventory management of study drug and comparators at depots
  • Maintain supply dashboards (eg. month-on-hand) and KPI’s
  • Work cross-functionally to ensure supply plans are feasible
  • Provide product costs to support international shipments
  • Develop and implement appropriate Supply Chain SOPs.

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$119.1M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

4%

1 year growth

10%

2 year growth

31%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.